OnKure Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
OnKure filed three exhibits: (1) a 2021 Stock Incentive Plan with 9.84M authorized shares (increased from 4.33M at Initial Closing, contingent on Series C financing completion); (2) a 2024 Equity Incentive Plan allowing performance-based RSU grants to employees; (3) an Outside Director Compensation Policy effective post-Merger (May 2024), providing annual cash retainers ($40K base; $4K–$30K additional for roles) and automatic equity grants (Options: 15.3K Closing Award, 60K Initial Award, 30K Annual Award). No specific counterparty dollar amounts or share counts for RSU vesting metrics appear in the documents provided.
Why this rating
Routine equity plan and compensation policy filings; boilerplate terms. No disclosed material grants, equity issuances, or financial impact to $28M market-cap company. Standard governance documents.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.